title: Serum cyclophilin A concentrations in renal transplant recipients receiving cyclosporine A: clinical implications for gingival overgrowth.
abstract: OBJECTIVE
  The aim of this study was to investigate the clinical factors in relation to the cyclosporine A (CsA) induced gingival overgrowth (GO).
  
  
  METHODS
  Seventy-three participants were assigned as GO+ and GO-. Factors including demographic, pharmacological, gingival variables and the serum cyclophilin A (CyPA) concentration were analyzed.
  
  
  RESULTS
  The occurrence of GO was 39.72%. Papillary bleeding index (PBI) had a significantly higher risk of GO than plaque index (PI), the ratio of CsA to CyPA, and serum CyPA concentration (odds ratio = 364.323, 25.791, 1.002, 0.096, respectively). The severity of GO correlated with PI, the ratio of CsA to CyPA, PBI, serum concentrations of CsA and CyPA (r = 0.366, 0.355, 0.344, 0.305, and -0.232, respectively).
  
  
  CONCLUSIONS
  Since a cross-sectional study is not able to explain whether plaque and inflammation are the cause or consequence of GO, the ratio of CsA to CyPA may be a valuable marker for predicting GO.
authors.affiliation: Department of Stomatology, Changzheng Hospital, Second Military Medical University, Shanghai, PR China.
authors.forename: Lei
authors.initials: L
authors.lastname: Jiang
authors.forename: Ming Jing
authors.initials: MJ
authors.lastname: Gao
authors.forename: Jie
authors.initials: J
authors.lastname: Zhou
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Shu Wei
authors.initials: SW
authors.lastname: Zhao
authors.forename: Yun Fu
authors.initials: YF
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D003430:Cross-Sectional Studies; D021984:Cyclophilin A / Q000097:blood*; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D003774:Dental Plaque Index; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D021984:Cyclophilin A